Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134652) titled 'Telmisartan plus Semaglutide for Hypertensive Obese Type 2 Diabetes' on Oct. 19.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Huashan Hospital, Fudan University
Condition:
Hypertension, Obesity, Type 2 diabetes mellitus
Intervention:
The control group:Amlodipine
Recruitment Status: Not Recruiting
Phase: 0
Date of First Enrollment: 2026-10-26
Target Sample Size: The control group:16;The Experimental group:16;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=343562
Disclaimer: Curated by HT Syndication....